94088-47-8

Basic information

• Product Name: 2,6-DIBENZYLOXYBENZONITRILE
• Synonyms: 2,6-DIBENZYLOXYBENZONITRILE;LABOTEST-BB LT00455273;2,6-bis(phenylmethoxy)benzonitrile;2,6-Dibenyloxy benzonitrile
• CAS NO: 94088-47-8
• Molecular Formula: C₂₁H₁₇NO₂
• Molecular Weight: 315.37
• EINECS: 302-048-0
• Product Categories: Aromatic Nitriles
• Mol File: 94088-47-8.mol
• Article Data: 3

Chemical Properties

• Melting Point: 122-124°C
• Boiling Point: 514.4°Cat760mmHg
• Flash Point: 178.9°C
• Appearance: /
• Density: 1.19g/cm³
• Vapor Pressure: 1.08E-10mmHg at 25°C
• Refractive Index: 1.625
• BRN: 2767023
• CAS DataBase Reference: 2,6-DIBENZYLOXYBENZONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-DIBENZYLOXYBENZONITRILE(94088-47-8)
• EPA Substance Registry System: 2,6-DIBENZYLOXYBENZONITRILE(94088-47-8)

Safety Data

• Safety Statements: 22-24/25
• Hazardous Substances Data: 94088-47-8(Hazardous Substances Data)

Usage

General Description

2,6-DIBENZYLOXYBENZONITRILE is a chemical compound with the molecular formula C21H19NO. It is a nitrile derivative, containing a benzyl ether and a benzonitrile functional group. 2,6-DIBENZYLOXYBENZONITRILE is used as a building block in the synthesis of various pharmaceuticals and organic compounds. It is also utilized as a reagent in organic synthesis and research. 2,6-DIBENZYLOXYBENZONITRILE is a white solid with a high melting point and is mainly used in laboratory settings for chemical reactions and as an intermediate in the production of other organic compounds.

InChI:InChI=1/C21H17NO2/c22-14-19-20(23-15-17-8-3-1-4-9-17)12-7-13-21(19)24-16-18-10-5-2-6-11-18/h1-13H,15-16H2

Upstream product

• 1897-52-5 2,6 difluorobenzonitrile 
• 22379-62-0 potassium benzyloxide 
• 20194-18-7 sodium phenyl-methanolate 

Relevant articles and documents

Anti-hepatitis c virus compound and its preparation method and application

The invention provides an anti-hepatitis C virus compound, a preparation method and an application thereof. The compound is the compound shown in a formula I or a stereisomer, a geometric isomer and a tautomer of the compound shown in the formula I, wherein R1 and R2 are respectively and independently selected from hydrogen, formyl group, benzoyl group and C1-C3 straight chain or branched chain alkyl group, and R1 and R2 can not be hydrogen at the same time. The compound has good lipid solubility and physical and chemical property, and bioavailability and effect in-vivo can be obviously increased.

Discovering potent small molecule inhibitors of cyclophilin A using de novo drug design approach

This work describes an integrated approach of de novo drug design, chemical synthesis, and bioassay for quick identification of a series of novel small molecule cyclophilin A (CypA) inhibitors (1-3). The activities of the two most potent CypA inhibitors (3h and 3i) are 2.59 and 1.52 nM, respectively, which are about 16 and 27 times more potent than that of cyclosporin A. This study clearly demonstrates the power of our de novo drug design strategy and the related program LigBuilder 2.0 in drug discovery.